CN116782940A - 用于治疗眼部疾病的组合物和方法 - Google Patents

用于治疗眼部疾病的组合物和方法 Download PDF

Info

Publication number
CN116782940A
CN116782940A CN202180090142.XA CN202180090142A CN116782940A CN 116782940 A CN116782940 A CN 116782940A CN 202180090142 A CN202180090142 A CN 202180090142A CN 116782940 A CN116782940 A CN 116782940A
Authority
CN
China
Prior art keywords
antibody
amino acid
seq
faba
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180090142.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·格罗夫
L·泰勒
T·耶德诺克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annexon Inc
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of CN116782940A publication Critical patent/CN116782940A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180090142.XA 2020-12-04 2021-12-03 用于治疗眼部疾病的组合物和方法 Pending CN116782940A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04
US63/121,629 2020-12-04
PCT/US2021/061755 WO2022120137A1 (en) 2020-12-04 2021-12-03 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
CN116782940A true CN116782940A (zh) 2023-09-19

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180090142.XA Pending CN116782940A (zh) 2020-12-04 2021-12-03 用于治疗眼部疾病的组合物和方法

Country Status (11)

Country Link
US (1) US20240059765A1 (https=)
EP (1) EP4255485A4 (https=)
JP (1) JP2023551734A (https=)
KR (1) KR20230117192A (https=)
CN (1) CN116782940A (https=)
AU (1) AU2021391800A1 (https=)
CA (1) CA3200976A1 (https=)
CL (1) CL2023001596A1 (https=)
IL (1) IL303289A (https=)
MX (1) MX2023006591A (https=)
WO (1) WO2022120137A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
KR20250006238A (ko) * 2022-04-29 2025-01-10 애넥슨, 인코포레이티드 안구 질환을 치료하기 위한 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) * 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Also Published As

Publication number Publication date
AU2021391800A1 (en) 2023-06-22
CL2023001596A1 (es) 2024-01-19
JP2023551734A (ja) 2023-12-12
EP4255485A4 (en) 2025-05-14
KR20230117192A (ko) 2023-08-07
US20240059765A1 (en) 2024-02-22
CA3200976A1 (en) 2022-06-09
EP4255485A1 (en) 2023-10-11
MX2023006591A (es) 2023-08-11
WO2022120137A1 (en) 2022-06-09
IL303289A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
CN116782940A (zh) 用于治疗眼部疾病的组合物和方法
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
SA111320266B1 (ar) أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
IL295414B2 (en) Compositions and methods for treating macular edema due to diabetes
JP2020519634A (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
AU2017299579A1 (en) Compositions and methods for treating frontotemporal dementia
JP2026028257A (ja) 血液障害を処置するための組成物及び方法
CN121729428A (zh) α4β7整联蛋白抗体组合物和使用方法
US20250313614A1 (en) Compositions and methods for treating ocular diseases
WO2023237928A2 (en) Igf1r antibodies
EA050212B1 (ru) Композиции и способы лечения болезней глаз
HK40101076A (zh) 用於治疗眼部疾病的组合物和方法
US20210371519A1 (en) Suppressing IgE-Mediated Allergy by Desensitization with Monovalent Anti-FCeR1a Monoclonal Antibody
HK40121733A (zh) 用於治疗眼部疾病的组合物和方法
RU2797348C2 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
JP2025533847A (ja) 抗ｃ１ｑ抗体のための製剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101076

Country of ref document: HK